MedPath

Early Intervention and Prevention of Non-Alcoholic Fatty Liver Disease in Adolescents

Not Applicable
Completed
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Behavioral: General Healthy Diet
Registration Number
NCT02116192
Lead Sponsor
University of Wisconsin, Madison
Brief Summary

This research study intends to learn about whether early intervention can help to prevent non-alcoholic fatty liver disease (NAFLD) in adolescents. Potentially eligible adolescents who are seen at the University of Wisconsin (UW) Pediatric Fitness Clinic will be asked to join the study. Patients who agree to participate in the study will be randomized into either the intervention group or the control group. The intervention group will follow a low-fructose diet. In addition, participants will be asked to return to the clinic for 4 follow-up visits during a 6-month interval.

Detailed Description

This will be a prospective, randomized, controlled trial for obese adolescents. Sixty obese youth (male and female), age 11-17 years with BMI \>95 %tile for age and sex and one parent/guardian will be recruited for inclusion into the study at an initial pediatric fitness clinic visit. Consented subjects will be stratified by gender and ethnicity and randomized into low fructose or standard weight loss dietary intervention groups.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
28
Inclusion Criteria
  • 11-17 years of age
  • BMI >95%tile for age and sex
  • Being seen for an initial clinic visit at the UW Pediatric Fitness Clinic
  • Parent willing to participate in study
Exclusion Criteria
  • History of chronic disease that effects hepatic or renal function including: Type 1 or Type 2 diabetes mellitus, known liver disease or other chronic illness.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
General Healthy DietGeneral Healthy DietControl: General Healthy Diet (Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg; 50-60% CHO, 15-20% Protein, 20-30% Fat)
Primary Outcome Measures
NameTimeMethod
Hepatic triglyceride content measured by Magnetic resonance (MR) PDFF6 months
Secondary Outcome Measures
NameTimeMethod
Novel free breathing hepatic MR PDFF protocol6 months
PNPLA3 genotype6 months
Metabolic biomarkers6 months

Including waist circumference (WC), blood pressure (BP), insulin resistance measured by homeostasis model assessment (HOMA-IR), lipids, ALT, androgens, and visceral and subcutaneous adiposity (by MR PDFF), and cardiovascular fitness (sub-maxVO2 test), in low carbohydrate/low fructose and standard weight-reduction diet groups

Trial Locations

Locations (1)

Research Park Clinic

🇺🇸

Madison, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath